Venture Capital Archives - Page 90 of 111 - Boston Life Sciences Times

Casma Therapeutics Secures $7.6 Million in MJFF Funding to Advance Parkinson’s Disease Program

March 10, 2026

NEJM Publishes Data Suggesting Zorevunersen May Modify Disease Course in Dravet Syndrome

March 5, 2026

Arsenal Medical Treats First Patient with ResQFoam Device for Life-Threatening Abdominal Bleeding

March 4, 2026

THIS WEEK'S STORIES

Casma Therapeutics Secures $7.6 Million in MJFF Funding to Advance Parkinson’s Disease Program

March 10, 2026

Parabilis Medicines Reports Early Clinical Data Showing Zolucatetide Reduces Polyp Burden in Familial Adenomatous Polyposis

March 5, 2026

MindImmune Secures $5 Million Investment from Alzheimer’s Drug Discovery Foundation to Advance Alzheimer’s Therapy

March 10, 2026

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Venture Capital

Cambridge Startup Axiomatic AI Raises $18M to Build Verified AI Platform for Engineering

Cognito Therapeutics Raises $105 Million Series C to Advance Alzheimer’s Therapy Platform

Poplar Therapeutics Raises $45 Million to Advance Anti-IgE Therapy for Food Allergy and Atopic Diseases

BreezeBio Raises $60 Million in Series B to Advance Precision Genetic Medicines Pipeline

Synthpop Raises $15 Million Series A to Expand AI Platform for Healthcare Workflow Automation

Most Read

Aurion Biotech Names Marjan Farid, M.D., Chair of Medical Advisory Board

Parabilis Medicines’ Zolucatetide Receives FDA Orphan Drug Designation for Desmoid Tumors

GelMEDIX, Catalent Partner to Develop Stem Cell-Based Therapies for Ocular and Retinal Diseases

Cognito Therapeutics Names Thomas Fagan Executive Vice President of Alzheimer’s Portfolio

EDITOR PICKS

Casma Therapeutics Secures $7.6 Million in MJFF Funding to Advance Parkinson’s Disease Program

NEJM Publishes Data Suggesting Zorevunersen May Modify Disease Course in Dravet Syndrome

Arsenal Medical Treats First Patient with ResQFoam Device for Life-Threatening Abdominal Bleeding

THIS WEEK'S STORIES

Casma Therapeutics Secures $7.6 Million in MJFF Funding to Advance Parkinson’s Disease Program

Parabilis Medicines Reports Early Clinical Data Showing Zolucatetide Reduces Polyp Burden in Familial Adenomatous Polyposis

MindImmune Secures $5 Million Investment from Alzheimer’s Drug Discovery Foundation to Advance Alzheimer’s Therapy

POPULAR CATEGORY

ABOUT US

FOLLOW US